US 12,116,366 B2
Azaindole rock inhibitors
Thomas Maxwell Kaiser, Charleston, SC (US)
Assigned to Avicenna Biosciences, Inc., Durham, NC (US)
Filed by Avicenna Biosciences, Inc., Durham, NC (US)
Filed on Mar. 19, 2024, as Appl. No. 18/610,041.
Application 18/610,041 is a continuation of application No. PCT/US2023/086402, filed on Dec. 29, 2023.
Claims priority of provisional application 63/436,408, filed on Dec. 30, 2022.
Prior Publication US 2024/0246972 A1, Jul. 25, 2024
Int. Cl. C07D 471/04 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 31/437 (2006.01); A61K 47/20 (2006.01); A61K 47/38 (2006.01)
CPC C07D 471/04 (2013.01) [A61K 9/0019 (2013.01); A61K 9/08 (2013.01); A61K 31/437 (2013.01); A61K 47/20 (2013.01); A61K 47/38 (2013.01)] 28 Claims
 
1. A compound of Formula:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof;
wherein:
R1 and R2 are independently selected from the group consisting of hydrogen, C1-C4 alkyl, C1-C4 haloalkyl, and halogen.